Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Conditions
X-Linked Retinitis Pigmentosa
Interventions
AAV5-RPGR
Genetic
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
5 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Conditions
Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
5 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
La Jolla, California • Stanford, California • Atlanta, Georgia + 3 more
Conditions
Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary, Retinal Diseases
Interventions
AAV OPTIRPE65
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 1Phase 2 Interventional Results available

Gene Therapy for Achromatopsia (CNGA3)

NCT03758404
Conditions
Achromatopsia
Interventions
adeno-associated virus vector AAV- CNGA3
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Achromatopsia
Interventions
Prior exposure to AAV-CNGA3 or AAV-CNGB3
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Leber Congenital Amaurosis
Interventions
Not listed
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy, Head and Neck Cancer
Interventions
AAV2hAQP1: 1 x 10^11 vg/gland (single gland), AAV2hAQP1: 3 x 10^10 vg/gland (both glands), AAV2hAQP1: 3 x 10^11 vg/gland (single gland), AAV2hAQP1: 1 x 10^11 vg/gland (both glands), AAV2hAQP1: 1 x 10^12 vg/gland (single gland), AAV2hAQP1: 3 x 10^11 vg/gland (both glands), AAV2hAQP1: 3 x 10^12 vg/gland (single gland), AAV2hAQP1: 1 x 10^12 vg/gland (both glands)
Drug
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Stanford, California • Louisville, Kentucky • Boston, Massachusetts + 2 more
Completed Phase 1Phase 2 Interventional Results available

Gene Therapy for Achromatopsia (CNGB3)

NCT03001310
Conditions
Achromatopsia
Interventions
AAV - CNGB3
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Leber Congenital Amaurosis
Interventions
AAV RPE65
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan